CLINICAL_TRIALS ClinicalTrials.gov record update

Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin®/MPA (PREMPRO®) and MPA Suspension (Provera®) in Healthy Postmenopausal Women

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00543634
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:03.962930+00:00
Published At: 2010-06-22T00:00:00+00:00
Record Updated At: 2010-06-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Postmenopause"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2010-06-22"
protocolSection.identificationModule.nctId: "NCT00543634"
protocolSection.identificationModule.officialTitle: "Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin\u00ae/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin\u00ae/MPA (PREMPRO\u00ae) and MPA Suspension (Provera\u00ae) in Healthy Postmenopausal Women"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.